[go: up one dir, main page]

AU2003255621A1 - Topical use of at least one double-stranded rna oligonucleotide (ds rna) - Google Patents

Topical use of at least one double-stranded rna oligonucleotide (ds rna)

Info

Publication number
AU2003255621A1
AU2003255621A1 AU2003255621A AU2003255621A AU2003255621A1 AU 2003255621 A1 AU2003255621 A1 AU 2003255621A1 AU 2003255621 A AU2003255621 A AU 2003255621A AU 2003255621 A AU2003255621 A AU 2003255621A AU 2003255621 A1 AU2003255621 A1 AU 2003255621A1
Authority
AU
Australia
Prior art keywords
double
rna
stranded rna
topical use
rna oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003255621A
Other versions
AU2003255621A8 (en
Inventor
Christine Collin-Djangone
Albert Duranton
Francis Pruche
Jean-Thierry Simonnet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0206796A external-priority patent/FR2840217B1/en
Application filed by LOreal SA filed Critical LOreal SA
Publication of AU2003255621A8 publication Critical patent/AU2003255621A8/en
Publication of AU2003255621A1 publication Critical patent/AU2003255621A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Birds (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

The invention relates to a novel use of at least one double-stranded RNA oligonucleotide (ds RNA) for a topical application and topical compositions comprising at least one double-stranded RNA oligonucleotide encapsulated within a physiologically-acceptable medium. The invention further relates to a cosmetic treatment method using at least one double-stranded RNA oligonucleotide.
AU2003255621A 2002-06-03 2003-06-02 Topical use of at least one double-stranded rna oligonucleotide (ds rna) Abandoned AU2003255621A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR0206796A FR2840217B1 (en) 2002-06-03 2002-06-03 COSMETIC COMPOSITIONS COMPRISING AT LEAST ONE DOUBLE-STRANDED RNA OLIGONUCLEOTIDE (DSRNA) AND USES THEREOF
FR02/06796 2002-06-03
US38672002P 2002-06-10 2002-06-10
US60/386,720 2002-06-10
PCT/FR2003/001648 WO2003101376A2 (en) 2002-06-03 2003-06-02 Topical use of at least one double-stranded rna oligonucleotide (ds rna)

Publications (2)

Publication Number Publication Date
AU2003255621A8 AU2003255621A8 (en) 2003-12-19
AU2003255621A1 true AU2003255621A1 (en) 2003-12-19

Family

ID=29713354

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003255621A Abandoned AU2003255621A1 (en) 2002-06-03 2003-06-02 Topical use of at least one double-stranded rna oligonucleotide (ds rna)

Country Status (8)

Country Link
EP (1) EP1513482B1 (en)
JP (1) JP4499554B2 (en)
AT (1) ATE464038T1 (en)
AU (1) AU2003255621A1 (en)
CA (1) CA2485111A1 (en)
DE (1) DE60332112D1 (en)
ES (1) ES2342826T3 (en)
WO (1) WO2003101376A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254214A1 (en) * 2002-11-20 2004-06-09 Beiersdorf Ag Oligoribonucleotides for the treatment of degenerative skin symptoms by RNA interference
GB0307914D0 (en) * 2003-04-07 2003-05-14 Univ Dundee Cytochrome p450
EP1689864A2 (en) * 2003-10-21 2006-08-16 Dyad Pharmaceutical Corporation Method and compositions for treating 5alpha-reductase type 1 and type 2 dependent conditions
DE102004025881A1 (en) 2004-05-19 2006-01-05 Beiersdorf Ag Oligoribonucleotides for influencing hair growth
WO2006040446A1 (en) * 2004-10-07 2006-04-20 L'oreal Method for shaping keratin fibres
WO2006040447A1 (en) * 2004-10-07 2006-04-20 L'oreal Method for cosmetic treatment of keratin fibres and use of a transglutaminase modulator
FR2885808B1 (en) 2005-05-19 2007-07-06 Oreal VECTORIZATION OF DSRNA BY CATIONIC PARTICLES AND TOPICAL USE.
US9139850B2 (en) 2005-05-19 2015-09-22 L'oreal Vectorization of dsRNA by cationic particles and topical use
FR2885813B1 (en) * 2005-05-19 2008-01-11 Oreal VECTORIZATION OF DSRNA BY CATIONIC PARTICLES AND THEIR USE ON SKIN MODEL.
FR2890859B1 (en) * 2005-09-21 2012-12-21 Oreal DOUBLE-STRANDED RNA OLIGONUCLEOTIDE INHIBITING TYROSINASE EXPRESSION
JP4981381B2 (en) * 2006-08-04 2012-07-18 株式会社ナリス化粧品 Skin external preparation for whitening
JP2008115101A (en) * 2006-11-02 2008-05-22 Naris Cosmetics Co Ltd Skin-bleaching composition
TWI382849B (en) * 2007-10-29 2013-01-21 Mello Biotech Taiwan Co Ltd Method of producing cosmetic product for skin care in ways of gene silencing effect and genetic recombinant nucleic acids encoding gene silencing effector
FR2940977B1 (en) * 2009-01-13 2016-11-18 Oreal USE OF COMPLEX FORMS OF THE CALMODULIN-LIKE SKIN PROTEIN CLSP PROTEIN
FR2986233B1 (en) * 2012-02-01 2014-02-28 Regentis Internat BIFUNCTIONAL PEPTIDE
FR3043695B1 (en) * 2015-11-17 2019-10-25 ISP Investments LLC. PROCESS FOR OBTAINING AQUEOUS EXTRACT ENRICHED IN SMALL RNA FROM PLANT MATERIAL AND EXTRACTS FROM THE PROCESS
FR3106754B1 (en) 2020-02-04 2022-01-07 Isp Investments Llc METHOD FOR OBTAINING AN AQUEOUS LAVENDER EXTRACT, COMPOSITIONS COMPRISING SUCH AN EXTRACT AND THEIR COSMETIC USES
US12442001B2 (en) 2020-04-03 2025-10-14 Medrx Co., Ltd. Double stranded RNA specifically inhibiting expression of IL-23 and pharmaceutical composition comprising same
FR3116438B1 (en) 2020-11-23 2022-10-14 Isp Investments Llc METHOD FOR OBTAINING AQUEOUS EXTRACTS FROM TEA LEAVES, COMPOSITIONS COMPRISING SUCH EXTRACTS AND THEIR COSMETIC USES
FR3125425B1 (en) 2021-07-22 2024-09-13 Isp Investments Llc BLACK TEA LEAF EXTRACT, COMPOSITIONS COMPRISING IT AND ITS COSMETIC USES

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9927444D0 (en) * 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
FR2804960B1 (en) * 2000-02-11 2005-06-24 Lvmh Rech NOVEL OLIGONUCLEOTIDES AND USE OF OLIGONUCLEOTIDES MODULATING THE EXPRESSION OF TYROSINASE AND TYROSINASE-RELATED-PROTEIN 1 AS DEPIGMENTING AGENTS

Also Published As

Publication number Publication date
CA2485111A1 (en) 2003-12-11
AU2003255621A8 (en) 2003-12-19
ATE464038T1 (en) 2010-04-15
DE60332112D1 (en) 2010-05-27
WO2003101376A3 (en) 2004-05-06
JP2005530812A (en) 2005-10-13
JP4499554B2 (en) 2010-07-07
EP1513482A2 (en) 2005-03-16
EP1513482B1 (en) 2010-04-14
ES2342826T3 (en) 2010-07-15
WO2003101376A2 (en) 2003-12-11

Similar Documents

Publication Publication Date Title
AU2003255621A1 (en) Topical use of at least one double-stranded rna oligonucleotide (ds rna)
AU2003279010A1 (en) Compositions and methods for delivery of short interfering rna and short hairpin rna
AU2001268126A1 (en) Compositions, kits, and methods for promoting defined health benefits
AU2001276048A1 (en) Rapid-melt semi-solid compositions, methods of making same and methods of using same
AU2001279284A1 (en) Rapid-melt semi-solid compositions, methods of making same and methods of using same
AU2003261449A1 (en) Compositions for rna interference and methods of use thereof
WO2004080406A3 (en) Therapeutic compositions
EP1911757B8 (en) Method of preparation of 3-(1,3-Dihydroimidazole-2-thione-1-yl)-chromanes and thiochromanes as dopamine-beta-hydroxylase inhibitors
AU2003235403A1 (en) Method of utilizing physiological activity of rare saccharide and compositions containing rare saccharide
GB0500265D0 (en) Methods and compositions relating to labeled rna molecules that reduce gene expression
WO2004058153A9 (en) Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
AU2003294784A1 (en) Hair treatment compositions
AU2002345353A1 (en) Methods and compositions that affect melanogenesis (pfi-016cip/pct)
AU2001275155A1 (en) Superoxide-generating diazeniumdiolates, compositions comprising same, and methods for using same
AU2003265972A1 (en) Composition and method to whiten skin
IL161039A0 (en) Mupirocin compositions for topical use, and improved process of making same and methods of using same
WO2005110009A8 (en) COMPOSITIONS AND METHODS RELATING TO TSP-30a, b, c AND d
AU2001268232A1 (en) Compositions, methods, and kits relating to resistin-like molecules
MXPA03011128A (en) Flavour and fragrance compositions.
AU2002239739A1 (en) Compositions, methods and kits relating to remodelin
AU2002360531A1 (en) Methods and compositions to treat cardiovascular disease using 1419, 58765 and 2201
WO2003002084A3 (en) Fragrance and flavour compositions
WO2002040637A3 (en) Antisense modulation of pi3k p85 expression
AU2003215633A1 (en) Hair treatment compositions
AU2003251755A1 (en) Methods, compositions and kits for treating damage to excitable tissue

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase